Skip to content

A Radiomic Model for Risk of Local Recurrence and DFS for T3 and T4 Non-small Cell Lung Cancer

Development of a Tumor and Peritumor Radiomics-based Model to Predict the High-risk Surgical Margin and Prognosis of T3 and T4 Non-Small Cell Lung Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06405815
Enrollment
200
Registered
2024-05-08
Start date
2021-01-01
Completion date
2023-12-31
Last updated
2024-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Nonsmall Cell

Keywords

non-small cell lung cancer, surgical margin, DFS, radiomics

Brief summary

The investigators retrospectively collected the participants with T3 and T4, N0-2, M0 NSCLC patients resected between January 2013 to December 2021 for training and internal validation. The Clinical data, preoperative laboratory results and images were collected. High-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up, and the investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSO was used to select the features and tumor radiomics model, peritumor model and combined model were built using 5-fold cross-validation. And it was further tested on the independent cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), sensibility, specificity.

Interventions

OTHERtumor and peritumor radiomic feature

extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT

Sponsors

Jinling Hospital, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* patients with T3 and T4 stage NSCLC; * available preoperative chest CTE within two weeks of surgery

Exclusion criteria

* inadequate imaging quality resulted from breathing artifact; * without regularly follow-up information on recurrence location and time

Design outcomes

Primary

MeasureTime frameDescription
disease free time and recurrence locationuntil the December 2023the time from the surgery time to the recurrence time

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026